Skip to main content
. 2011 Oct 28;6:146. doi: 10.1186/1748-717X-6-146

Table 1.

OAR dose constraints used for planning for the phase I trial

Critical Structure Dose Limits
Serial Tissue Volume Volume Max (Gy) Max Point Dose (Gy) Endpoint (≥ Grade 3)
Spinal Cord and medulla < 0.35 cc 10 Gy 14 Gy myelitis
< 1.2 cc 7 Gy
Spinal Cord Subvolume (5-6 mm above and below level treated) < 10% of subvolume 10 Gy 14 Gy myelitis
Skin < 10 cc 23 Gy 26 Gy ulceration
Stomach < 10 cc 11.2 Gy 12.4 Gy ulceration/fistula
Duodenum* < 5 cc
< 10 cc
11.2 Gy
9 Gy
12.4 Gy ulceration
Jejunum/Ileum* < 5 cc 11.9 Gy 15.4 Gy enteritis/obstruction
Colon* < 20 cc 14.3 Gy 18.4 Gy colitis/fistula
Liver 700 cc 9.1 Gy Basic Liver Function
Renal cortex (Right & Left) 200 cc 8.4 Gy Basic renal function